Natural products to drugs: daptomycin and related lipopeptide antibiotics

被引：282

作者：

Baltz, RH ^{[1
]}

Miao, V ^{[1
]}

Wrigley, SK ^{[1
]}

机构：

[1] Cubist Pharmaceut Inc, Lexington, MA 02421 USA

来源：

NATURAL PRODUCT REPORTS | 2005年 / 22卷 / 06期

关键词：

D O I：

10.1039/b416648p

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Daptomycin (Cubicin(R)) is a lipopeptide antibiotic approved in the USA in 2003 for the treatment of skin and skin structure infections caused by Gram-positive pathogens. It is a member of the 10-membered cyclic lipopeptide family of antibiotics that includes A54145, calcium-dependent antibiotic (CDA), amphomycin, friulimicin, laspartomycin, and others. This review highlights research on this class of antibiotics from 1953 to 2005, focusing on more recent studies with particular emphasis on the interplay between structural features and antibacterial activities; chemical modi. cations to improve activity; the genetic organization and biosynthesis of lipopeptides; and the genetic engineering of the daptomycin biosynthetic pathway to produce novel derivatives for further chemical modi. cation to develop candidates for clinical evaluation.

引用

收藏

页码：717 / 741

页数：25

相关论文

共 235 条

[1] DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS [J].

ALBORN, WE ;

ALLEN, NE ;

PRESTON, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2282-2287

[2] Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection [J].

Alder, J ;

Li, TC ;

Yu, DH ;

Morton, L ;

Silverman, J ;

Zhang, XX ;

Critchley, I ;

Thorne, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3561-3566

[3] Daptomycin, a new drug class for the treatment of gram-positive infections [J].

Alder, JD .

DRUGS OF TODAY, 2005, 41 (02) :81-90

[4]

ALEXANDER D, 2005, SOC IND MICR ANN M C

[5]

Alexander D., 2004, GENETICS MOL BIOL IN

[6] INHIBITION OF MEMBRANE POTENTIAL-DEPENDENT AMINO-ACID-TRANSPORT BY DAPTOMYCIN [J].

ALLEN, NE ;

ALBORN, WE ;

HOBBS, JN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) :2639-2642

[7] INHIBITION OF PEPTIDOGLYCAN BIOSYNTHESIS IN GRAM-POSITIVE BACTERIA BY LY146032 [J].

ALLEN, NE ;

HOBBS, JN ;

ALBORN, WE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1093-1099

[8] Genetic and transcriptional analysis of absA, an antibiotic gene cluster-linked two-component system that regulates multiple antibiotics in Streptomyces coelicolor [J].

Anderson, TB ;

Brian, P ;

Champness, WC .

MOLECULAR MICROBIOLOGY, 2001, 39 (03) :553-566

[9] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[10] Friulimicins:: Novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp nov I.: Taxonomic studies of the producing microorganism and fermentation [J].

Aretz, W ;

Meiwes, J ;

Seibert, G ;

Vobis, G ;

Wink, J .

JOURNAL OF ANTIBIOTICS, 2000, 53 (08) :807-815

← 1 2 3 4 5 6 7 8 9 10 →